FTI Consulting Set to Join S&P MidCap 400; KKR Real Estate Finance Trust to Join S&P SmallCap 600 PR Newswire NEW YORK, Oct. 24, 2019 NEW YORK, Oct. 24, 2019 /PRNewswire/ -- S&P...
By Olivia Bugault Dassault Systemes SE (DSY.FR) said Thursday that the Committee on Foreign Investment in the United States has approved its proposed acquisition of Medidata Solutions Inc. (MDSO...
Study Site Analytics, available through iMedidata.com, helps sites manage performance with a dashboard providing consistent, standardized metrics across sites Dashboard includes metrics for...
Company Celebrates 20 Years of Innovation Under Tarek Sherif’s Leadership; Transforming Drug Development and Clinical Trial Technology Medidata celebrates 20 years of innovation as the...
Life Science Executives Agree that Precision Medicine Represents a New Era in Drug Development, According to the Newsweek Vantage and Medidata Survey Report Investment in IT systems is one of...
Faster, Simpler, Better: Dramatically Reduce Timelines, Simplify Study Start up, and Increase Quality in Hundreds of Clinical Trials Each Year New Medidata and MRT collaboration will seek to...
Medidata (NASDAQ:MDSO) today announced its financial results for the second quarter of 2019. “Our good results in the second quarter and for the first half of the year were driven by the strength...
Medidata (NASDAQ: MDSO) today announced that it will release its second quarter 2019 results after the close of U.S. financial markets on Tuesday, July 23, 2019. Due to the company's pending...
Catalyst adopts unified platform approach to immediately offer impactful and competitive services for biopharmaceutical companies New full service offerings adopt Medidata Rave CTMS, combined...
Medidata Rave Clinical Cloud™ to help spearhead the company’s biologics transformation Unified platform creates a single source of truth for all data, enabling teams to focus on critical...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.